These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34728241)

  • 1. Age at Parkinson's disease onset modulates the effect of levodopa on response inhibition: Support for the dopamine overdose hypothesis from the antisaccade task.
    Waldthaler J; Stock L; Krüger-Zechlin C; Timmermann L
    Neuropsychologia; 2021 Dec; 163():108082. PubMed ID: 34728241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levodopa medication improves incidental sequence learning in Parkinson's disease.
    Beigi M; Wilkinson L; Gobet F; Parton A; Jahanshahi M
    Neuropsychologia; 2016 Dec; 93(Pt A):53-60. PubMed ID: 27686948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisaccades in Parkinson's Disease: A Meta-Analysis.
    Waldthaler J; Stock L; Student J; Sommerkorn J; Dowiasch S; Timmermann L
    Neuropsychol Rev; 2021 Dec; 31(4):628-642. PubMed ID: 33742354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levodopa improves response inhibition and enhances striatal activation in early-stage Parkinson's disease.
    Manza P; Schwartz G; Masson M; Kann S; Volkow ND; Li CR; Leung HC
    Neurobiol Aging; 2018 Jun; 66():12-22. PubMed ID: 29501966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parkinson's disease duration determines effect of dopaminergic therapy on ventral striatum function.
    MacDonald AA; Monchi O; Seergobin KN; Ganjavi H; Tamjeedi R; MacDonald PA
    Mov Disord; 2013 Feb; 28(2):153-60. PubMed ID: 23165957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association between Parkinson's disease symptom side-of-onset and performance on the MDS-UPDRS scale part IV: Motor complications.
    Bay AA; Hart AR; Michael Caudle W; Corcos DM; Hackney ME
    J Neurol Sci; 2019 Jan; 396():262-265. PubMed ID: 30537631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Acute Dopamine Replacement on Cognitive Function in Parkinson's Disease.
    Seemiller J; Morrow C; Hinkle JT; Perepezko K; Kamath V; Pontone GM; Mills KA
    Mov Disord Clin Pract; 2024 May; 11(5):534-542. PubMed ID: 38470011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levodopa influences striatal activity but does not affect cortical hyper-activity in Parkinson's disease.
    Martinu K; Degroot C; Madjar C; Strafella AP; Monchi O
    Eur J Neurosci; 2012 Feb; 35(4):572-83. PubMed ID: 22304628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta-band oscillations in the supplementary motor cortex are modulated by levodopa and associated with functional activity in the basal ganglia.
    Chung JW; Burciu RG; Ofori E; Coombes SA; Christou EA; Okun MS; Hess CW; Vaillancourt DE
    Neuroimage Clin; 2018; 19():559-571. PubMed ID: 29984164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopaminergic substitution in Parkinson's disease.
    Müller T
    Expert Opin Pharmacother; 2002 Oct; 3(10):1393-403. PubMed ID: 12387685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopaminergic therapy and prefrontal activation during walking in individuals with Parkinson's disease: does the levodopa overdose hypothesis extend to gait?
    Dagan M; Herman T; Bernad-Elazari H; Gazit E; Maidan I; Giladi N; Mirelman A; Manor B; Hausdorff JM
    J Neurol; 2021 Feb; 268(2):658-668. PubMed ID: 32902733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Iowa Gambling Task in Parkinson's disease: A meta-analysis on effects of disease and medication.
    Evens R; Hoefler M; Biber K; Lueken U
    Neuropsychologia; 2016 Oct; 91():163-172. PubMed ID: 27475264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Movement chunking during sequence learning is a dopamine-dependant process: a study conducted in Parkinson's disease.
    Tremblay PL; Bedard MA; Langlois D; Blanchet PJ; Lemay M; Parent M
    Exp Brain Res; 2010 Sep; 205(3):375-85. PubMed ID: 20680249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa slows prosaccades and improves antisaccades: an eye movement study in Parkinson's disease.
    Hood AJ; Amador SC; Cain AE; Briand KA; Al-Refai AH; Schiess MC; Sereno AB
    J Neurol Neurosurg Psychiatry; 2007 Jun; 78(6):565-70. PubMed ID: 17178817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopaminergic Effect on Non-Motor Symptoms in Late Stage Parkinson's Disease.
    Rosqvist K; Odin P; Hagell P; Iwarsson S; Nilsson MH; Storch A
    J Parkinsons Dis; 2018; 8(3):409-420. PubMed ID: 30056433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. It's all in the type of the task: Dopamine modulates kinematic patterns during competitive vs. cooperative interaction in Parkinson's disease.
    Straulino E; Scaravilli T; Bulgheroni M; D'Amico E; Castiello U
    Neuropsychologia; 2016 Dec; 93(Pt A):106-115. PubMed ID: 27756693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine asymmetry interacts with medication to affect cognition in Parkinson's disease.
    Tomer R; Aharon-Peretz J; Tsitrinbaum Z
    Neuropsychologia; 2007 Jan; 45(2):357-67. PubMed ID: 16876208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paradoxical effect of dopamine medication on cognition in Parkinson's disease: relationship to side of motor onset.
    Hanna-Pladdy B; Pahwa R; Lyons KE
    J Int Neuropsychol Soc; 2015 Apr; 21(4):259-70. PubMed ID: 25923830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.